Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Management of morphologic changes associated with antiretroviral use in HIV-infected patients.

Wohl DA, Brown TT.

J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S93-S100. doi: 10.1097/QAI.0b013e318186521a. Review.

PMID:
18725818
2.
3.

Body-fat abnormalities in patients with HIV: progress and challenges.

Bedimo RJ.

J Int Assoc Physicians AIDS Care (Chic). 2008 Nov-Dec;7(6):292-305. doi: 10.1177/1545109708328931. Epub 2008 Dec 3. Review.

PMID:
19056708
5.

Disorders of body fat distribution in HIV-1-infected patients.

Moreno S, Miralles C, Negredo E, Domingo P, Estrada V, Gutiérrez F, Lozano F, Martínez E.

AIDS Rev. 2009 Jul-Sep;11(3):126-34. Review.

PMID:
19654854
6.

HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.

Kotler DP.

J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S79-85. doi: 10.1097/QAI.0b013e318186519c. Review.

PMID:
18725816
7.

[Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].

Streinu-Cercel A, Ion DA, Chivu LI, Chivu RD.

Rev Med Chir Soc Med Nat Iasi. 2006 Jul-Sep;110(3):521-5. Review. Romanian.

PMID:
17571539
8.

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.

Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD; HIV Outpatient Study Investigators..

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):48-56.

PMID:
12514413
9.

Metabolic complications of antiretroviral therapy.

Sweet DE.

Top HIV Med. 2005 Jun-Jul;13(2):70-4. Review.

10.

Lipodystrophy and quality of life of HIV-infected persons.

Guaraldi G, Murri R, Orlando G, Squillace N, Stentarelli C, Zona S, Garlassi E, Martínez E.

AIDS Rev. 2008 Jul-Sep;10(3):152-61. Review.

PMID:
18820717
11.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
12.

Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

Nolan D, Mallal S.

Sex Health. 2005;2(3):153-63. Review.

PMID:
16335543
13.

HIV and increased risk of cardiovascular diseases.

Das S.

Sex Health. 2005;2(4):219-21. Review.

PMID:
16402668
14.

Long-term complications of antiretroviral therapy: lipoatrophy.

Waters L, Nelson M.

Int J Clin Pract. 2007 Jun;61(6):999-1014. Review.

PMID:
17504362
15.

Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

Sattler FR.

Top HIV Med. 2008 Oct-Nov;16(4):127-33. Review.

16.

Switching strategies to improve lipid profile and morphologic changes.

Barragan P, Fisac C, Podzamczer D.

AIDS Rev. 2006 Oct-Dec;8(4):191-203. Review.

PMID:
17219734
17.

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S.

J Infect Dis. 2007 Jun 15;195(12):1754-61. Epub 2007 May 2.

PMID:
17492590
18.
19.

Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.

Barbaro G.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):337-43.

PMID:
16101566
20.

Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.

Guaraldi G, De Fazio D, Orlando G, Murri R, Wu A, Guaraldi P, Esposito R.

Clin Infect Dis. 2005 Jan 15;40(2):e13-5. Epub 2004 Dec 21.

PMID:
15655734

Supplemental Content

Support Center